linjc16/ctgov huggingface dataset:
Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors

Study Overview
=================
Brief Summary
-----------------
This proof of concept study will evaluate the ability of a new, ultrasound based technology called Bullseye Constructive Shearwave Interference (CSI) (trade name, Bullseye Elasticity Quantification) to measure lymphedema of the upper arm among breast cancer survivors. The study's hypothesis is that the CSI device can detect the presence of clinically significant lymphedema when compared with the standard arm tape measurement.

Official Title
-----------------
A Pilot Study of Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors

Conditions
-----------------
Lymphedema of Upper Arm, Breast Cancer

Intervention / Treatment
-----------------
* Device: Constructive Shearwave Interference (CSI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any subject with a history of unilateral breast cancer who has completed definitive treatment for breast cancer (i.e. previously undergone surgical resection, with or without adjuvant radiotherapy and/or chemotherapy). Subjects must have completed all recommended adjuvant radiotherapy. Subjects who continue on systemic therapy may be included at the discretion of the treating physician. Subjects with a history of unilateral axillary sentinel biopsy, lymphadenectomy or dissection are eligible for inclusion. Subjects taking hormonal therapy are eligible for inclusion Subject has any stage lymphedema Exclusion Criteria: Active rash or skin tears/injury in bilateral upper extremities Subjects with history of contralateral breast cancer treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CSI ultrasound measurement<br>Participants will have standard volumetric tape measurement across multiple arm locations for lymphedema followed by CSI ultrasound measurements of the same anatomic sites. | Device: Constructive Shearwave Interference (CSI)<br>* handheld ultrasound<br>* Other names: Bullseye Elasticity Quantification;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in mean shear wave speed across sites measured between lymphedema and non-lymphedema limbs | differences in shear wave speed (Bullseye) device measurements between lymphedema affected and non-affected contralateral limb | baseline |
Non-microradical Resection Margin as a Predictor for Recurrence After Complete Mesocolic Excision

Study Overview
=================
Brief Summary
-----------------
The study aim to investigate the value of the current definition of microradical resection margin in colon cancer. Is the distance from tumor tissue to resection margin and the site of any clinically prognostic importance if complete mesocolic excision has been performed.

Official Title
-----------------
Non-microradical Resection Margin as a Predictor for Recurrence After Complete Mesocolic Excision: a Prospective Cohort Study

Conditions
-----------------
Colon Cancer

Intervention / Treatment
-----------------
* Procedure: Complete mesocolic excision


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing elective curative intended complete mesocolic excision for primary colon adenocarcinoma at Nordsjællands Hospital in Hillerød, Denmark International Union Against Cancer (Union Internationale Contre le Cancer - UICC) stage III - pT1-4, pN1-2 cM0 (gastroepiploic and infrapyloric lymph node metastases are not considered as distant metastases) Resident in Denmark at the time of surgery. Exclusion Criteria: Patients who did not undergo macroradical resections Synchronous colorectal cancer Venous invasion at central venous ligation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Complete mesocolic excision|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence | Any type of recurrence | 3 years |
Efficacy of Intravenous Dexketoprofen and Tenoxicam on Propofol Associated Injection Pain

Study Overview
=================
Brief Summary
-----------------
Propofol remains the most common drug for induction of general anaesthesia, although it causes considerable pain or discomfort on injection. Anesthesia providers have attempted a large number of remedies to prevent this pain on injection. Previously explored ideas include injecting propofol into larger veins, warming of the hand with hot packs, and intravenous pretreatment with numerous other medications. No studies to date have looked at the dexketoprofen and tenoxicam for the pretreatment of pain on injection caused by propofol. The investigators propose studying the use of dexketoprofen and tenoxicam for pretreatment of propofol related pain on injection.

Conditions
-----------------
Injection Pain

Intervention / Treatment
-----------------
* Drug: saline
* Drug: dexketoprofen
* Drug: tenoxicam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status 1 and 2 18 - 65 years general anesthesia scheduled for elective surgery Exclusion Criteria: age < 18 years, > 65 years pregnancy patients requiring a rapid sequence induction refusal to participate and patients already participating in another study allergy to study drugs communication difficulty psychiatric and neurolojic disorders use of analgesics or sedative drugs within 24 hours before surgery. emergency surgery history of drug or alcohol abuse ASA 3 and above

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: saline<br> | Drug: saline<br>* before the anesthesia induction, 2mL saline iv injection<br>* Other names: serum physiologic;|
| Active Comparator: dexketoprofen<br> | Drug: dexketoprofen<br>* before the anesthesia induction, 50 mg (2mL) iv dexketoprofen<br>* Other names: Leodex;|
| Active Comparator: tenoxicam<br> | Drug: tenoxicam<br>* before the anesthesia induction, 20 mg (2mL) iv tenoxicam<br>* Other names: Tilcotil;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Verbal Pain Score |  | Approximately one minute following administration of propofol. | 
| Facial Pain Score |  | Approximately one minute following administration of propofol. |
A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C

Conditions
-----------------
HDL Cholesterol

Intervention / Treatment
-----------------
* Drug: MK0733 / Duration of Treatment: 18 Weeks
* Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has stable Type 2 diabetes mellitus at Visit 1. Patient meets screening criteria based on Visit 1 lab tests Exclusion Criteria: Patient is pregnant, breastfeeding, or at risk of becoming pregnant Patient has heart disease, uncontrolled high blood pressure, or other significant disease Patient is taking prohibited medication(s) and is unable to stop taking them for the duration of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0733 / Duration of Treatment: 18 Weeks|nan|
|Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HDL-C raising effects after 6 weeks |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect on other lipids and lipoproteins at 6 weeks |  | 6 weeks |
Cyberbullying Among Sohag University Student

Study Overview
=================
Brief Summary
-----------------
Cyberbullying can be defined as intentional aggression through electronic routes, such as text messages, e-mails, chat rooms, online games, and social websites. In comparison with traditional bullying, cyberbullying has many unique characteristics that boost its harmful effects, including the inability to avoid bullying, presence of larger and more potential audience, the continuity of bullying regardless of time or place, and the anonymity of perpetrator in many occasions .

Detailed Description
-----------------
In Egypt almost half of Beni-sueif university students (48.2%) reported experiencing cyberbullying victimization. Female students, students living in urban areas and those who spent more hours using the internet reported more exposure (p<0.001). Harassment was the main type stated by females (79.8%) while flaming was excessively reported by males (51.8%). Students responded mostly by anger (63.1%), hatred (23.2%) and sorrow (22.6%) towards the worst victimization incidents. In this study I want to study the situation of cyberbullying among Sohag University students . , study patterns of cyberbullying among Sohag University students , determine of correlates of cyberbullying among Sohag University students such as family factors and study the implications of cyberbullying on victims .

Official Title
-----------------
Cyberbullying Among Sohag University Students , Egypt .

Conditions
-----------------
Cyberbullying Among Sohag University Students

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: students of the selected faculties Exclusion Criteria: students who will refuse to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| study the situation of cyberbullying among Sohag University students | study the prevalence , the pattern and correlates of cyberbullying | 2022-2023 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cyberbullying
Infant Feeding Study.09-68

Study Overview
=================
Brief Summary
-----------------
Characterize a population-based sample of first-time expectant mothers with regards to maternal metabolic health and their infant feeding experience.

Detailed Description
-----------------
The long range purpose of this pilot study is to inform the development of an NIH-funded randomized intervention trial designed to improve early breastfeeding outcomes for mothers planning to breastfeed. The purpose of the pilot study is to 1) described the prenatal infant feeding attitudes and intentions of population-based sample of expectant mothers from the same recruitment base as the future intervention trial, 2) characterize the metabolic health profiles of the sample and 3) estimate the prevalence of early lactation difficulties among the subset of this sample that initiates breastfeeding.

Official Title
-----------------
The Infant Feeding Experience of New Mothers - a Descriptive Pilot Study.

Conditions
-----------------
Describe the Infant Feeding Attitudes, Intentions of a Sample of Expectant First-time Mothers, Estimate the Prevalence of Early Lactation Difficulties

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First-time expectant mother, speaks English, receiving OB care at designated practice group Exclusion Criteria: 1) Under 18 years old; 2)no access to local telephone 3) multiple gestation 4) history of major breast surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early lactation difficulties | a)Estimate the prevalence of early lactation difficulties among the subset of this sample that initiates breastfeeding, b) examine the relationship between metabolic health and lactation difficulties | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infant feeding attitudes | describe the prenatal infant feeding attitudes and intentions of a sample of expectant mothers from the same recruitment base as the future intervention trial | 1 year |
Fetal Nasal Bone Length Nomogram at 11-13wk+6days in Upper Egyptian Pregnant Women

Study Overview
=================
Brief Summary
-----------------
establish a reference values for the fetal nasal bone length (NBL) in upper egyptian pregnant women at 11-13wk+6 days

Detailed Description
-----------------
By using ultrasound measure fetal nasal bone length at 11-13wk+6days in Upper Egyptian pregnant women in mid-sagittal view in single pregnancy

Official Title
-----------------
Fetal Nasal Bone Length Nomogram at 11-13wk+6 Days in Upper Egyptain Pregnant Women

Conditions
-----------------
Nasal Bone Length

Intervention / Treatment
-----------------
* Other: Utrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal antenatal women of gestational age between 11 to 13week +6days. Single pregnancy. Viable fetus. No fetal malformation. No previous history of fetal malformation Exclusion Criteria: Medical diseased women . Multiple gestations . Fetal malformations . Missed abortion .
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Utrasound|Ultrasound examination|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal nasal bone length nomogram | Establish nomogram for nasal bone length in Upper Egyptian pregnant women | 2 years |
Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to show that Hemospray is effective in achieving initial hemostasis and documenting rate of further bleed when compared to standard of care.

Official Title
-----------------
Clinical Evaluation of Hemospray: Hemostasis of Active GI Luminal Tract Bleeding

Conditions
-----------------
Bleeding Peptic Ulcers

Intervention / Treatment
-----------------
* Device: Hemospray Kit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bleeding peptic ulcer Exclusion Criteria: Patient is: < 18 years of age Patient is unable to consent Patient is contraindicated to undergo endoscopy Patient has: coagulopathy, altered post surgical anatomy of the stomach, previously placed intrahepatic portosystemic shunt Patient is pregnant or lactating Patinet has an INR > 2.5

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hemospray Treatment<br>Hemospray Kit | Device: Hemospray Kit<br>* Hemostasis of Arterial GI Bleeding<br>* Other names: Endoscopic Hemostasis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with further bleed |  | 72 Hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with initial hemostasis |  | At the conclusion of the index procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endoscopic Hemostasis, Peptic Ulcer, Recurrent Bleeding, Injection Therapy, Thermal Probe
Assessment of the Neurosensory Alteration After Inferior Alveolar Nerve Lateralization

Study Overview
=================
Brief Summary
-----------------
: Assessment of the neurosensory alteration with computer guided inferior alveolar nerve lateralization versus non guided classic technique and measuring stability of implant after placement

Official Title
-----------------
Assessment of the Neurosensory Alteration With Computer Guided Inferior Alveolar Nerve Lateralization Versus Non Guided Classic Technique

Conditions
-----------------
Implant Site Reaction

Intervention / Treatment
-----------------
* Other: computer guided IAN lateralization surgical technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with with atrophied posterior mandibular ridge both sexes NO intra oral soft and hard tissue pathology NO systematic that contraindicate implant placement Exclusion Criteria: Presence pathological lesion Heavy smokers more than 20 cigarettes per day. patients with systemic disease that may affect normal healing
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: atrophic posterior mandible requiring nerve lateralization
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: computer gaiuded IAN<br>Computer guided surgical technique | Other: computer guided IAN lateralization surgical technique<br>* Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique<br>|
| Experimental: Classical technique<br>Non computer guided surgical technique | Other: computer guided IAN lateralization surgical technique<br>* Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the neurosensory alteration- sensation over time subjective(a scale 1-10) | assessing the sensation regaining over time subjective (a scale 1-10 ) | 2 months up to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant stability | Measurements of the implant stability immediately after placement by osstell | At the placement and after exposure ( up to 6 months ) |
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of weekly administered combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer. The primary endpoint will be the response rate.

Detailed Description
-----------------
Gastric cancer is the most frequently occurring malignancy in Korea, and is one of the main causes of cancer death. While treatment options for AGC have expanded in recent years to include newer agents such as taxanes, irinotecan and oxaliplatin, myelosuppression remains a problem. Recently, weekly schedule of docetaxel is appealing due to limited incidence of severe myelosuppression compared with standard 3-weekly regimen. This altered toxicity profile suggests a potential for better tolerance and increased dose intensity.

Official Title
-----------------
A Randomized Phase II Trial of Weekly Docetaxel/Cisplatin Versus Weekly Docetaxel/Oxaliplatin in Previously Untreated Patients With Advanced Gastric Cancer

Conditions
-----------------
Stomach Neoplasm, Stage IV, Recurrent

Intervention / Treatment
-----------------
* Drug: oxaliplatin
* Drug: Cisplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically proven gastric cancer aged 75 years or less performance status 0 to 2 no prior chemotherapy inoperable, recurrent, or metastatic normal marrow, hepatic and renal functions Exclusion Criteria: active infections severe co-morbidities pregnant or lactating women active brain metastasis neuropathy of grade 2 or higher

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks. | Drug: Cisplatin<br>* Cisplatin 60 mg/m2 will be given on day 1.<br>|
| Experimental: 2<br>Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks. | Drug: oxaliplatin<br>* oxaliplatin 120 mg/m2 will be given on day 1.<br>* Other names: Eloxatin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety |  |  |